

CURRICULUM VITAE

Name: Paul Richard Billings, MD, PhD, FACP, FACMG

President and CEO
Cellpoint Diagnostics, Inc.
265 N. Whisman Road
Mountain View, CA 94043

Chairman
Signature Genomics Laboratories, LLC.
120 North Pine Street
Spokane, WA 99202

Professor (Adjunct)
Department of Anthropology
University of California at Berkeley
Room 311 Kroeber Hall
Berkeley, CA 94720

Contacts: 650.938.9800 (Cellpoint) 510.549.1955 (Home)
510.549.1935 (Home office) 510.289.1890 (Cell)
888.614.0540 (Pager)
425.671.1187 (Fax)
paul@cellpointdiagnostics.com
billings@signaturegenomics.com
prbillings@earthlink.net (Personal)

Medical/DEA License #: 53720 (MA), G42450 (CA), 19354 (WA), AB1211806 (DEA) lapsed

Education:

1970-72		U.C. Santa Cruz
1972-74	A.B.	U.C. San Diego (<i>summa cum laude</i>)
1974-79	M.D.	Harvard Medical School
1976-79	Ph.D.	Immunology, Harvard University Graduate School of Arts and Sciences, (Baruj Benacerraf, MD Thesis Supervisor)

Post-Doctoral Training:

Internship and Residencies:

- 1979-80 University of Washington Affiliated Hospitals, Internal Medicine/Primary Care
1981-82 University of Washington Affiliated Hospitals, Internal Medicine

Clinical and Research Fellowships:

- 1972-74 Student Fellow, Salk Institute of Biological Sciences, Martin Kagnoff, M.D.,
Advisor
1973 Student Summer Fellow, American Gastroenterology Association, Morton
Grossman, M.D., Advisor
1976-79 Medical Scientist Training Grant Fellowship, NIH and Harvard University
1982-84 Fellow, Medical Genetics, University of Washington Affiliated Hospitals, Arno
Motulsky, M.D., Advisor
1984-86 Clinical and Research Fellow, Department of Medicine, Harvard Medical School,
Division of Immunopathology, Dana-Farber Cancer Institute, Harvey Cantor,
MD., Advisor

Academic Appointments:

- 1984 Winter Acting Assistant Professor, Department of Genetics, University of Washington
1985-88 Instructor, Department of Pathology, Harvard Medical School and Dana Farber
Cancer Institute
1987-89 Visiting Scientist, Cancer Research Center, Massachusetts Institute of Technology
1988-90 Instructor, Department of Medicine, Harvard Medical School
1990-97 Assistant Clinical Professor, Department of Medicine, UCSF School of Medicine
1990-92 Visiting Scientist, Lawrence Berkeley National Laboratory
1993-95 Associate Clinical Professor, Department of Medicine, Stanford University
Medical School
1995-97 Acting Associate Professor, Department of Medicine, Stanford University
Medical School
2000-02 Visiting Professor, Department of Anthropology, University of California at
Berkeley
2003- Adjunct Professor, Department of Anthropology, University of California at
Berkeley

Hospital/Clinical Appointments:

- 1980-81 Staff Physician, Southern California Permanente Medical Group
1982-84 Staff Physician (intermittent), Seattle Veterans Administration Hospital
1984-86 Clinical Fellow, Department of Medicine, Massachusetts General Hospital
1984-88 Staff Physician (intermittent), Boston Veterans Administration Hospital
1984-89 Clinical Fellow, Department of Medicine, Peter Bent Brigham Hospital

1986-90 Graduate Assistant, Department of Medicine, Massachusetts General Hospital
1987-90 Director, Clinic for Inherited Diseases, Department of Medicine, Deaconess Hospital
1988-90 Chief, Medical Services, Massachusetts Mental Health Center
1989-90 Staff Physician, Brigham and Women's Hospital
1990-92 Vice-Chairman, Department of Medicine, California Pacific Medical Center/Pacific Campus
1990-93 Chief, Division of Genetic Medicine, California Pacific Medical Center
1990-97 Staff Physician, San Francisco General Hospital
1993-94 Chief Medical Officer, San Jose Satellite Outpatient Clinic
1993-94 Chief, Division of General Internal Medicine, Veterans Affairs Medical Center, Palo Alto
1993-97 Staff Physician, Stanford University Hospital
1994-97 Deputy Chief of Staff, Satellite Clinic Operations, Veterans Affairs Medical Center, Palo Alto
1997-00 Deputy Network Director, VHA Heart of Texas Veterans Health Care System
1997-00 Chief Medical Officer, VHA Heart of Texas Veterans Health Care System
1997-00 Chief Academic Affiliations Officer, VHA Heart of Texas Veterans Health Care System
1998 Quality Management Officer, VHA Heart of Texas Veterans Health Care System

Corporate Appointments:

1994 C0-Founder and Medical Director, CBR Systems
1999- Co-Founder, GeneSage, Inc.
2000-02 Executive Vice President, Chief Scientific and Medical Officer, GeneSage, Inc.
2002-03 Vice President for Life Sciences and Clinical Affairs, WIPRO, Ltd.
2003 Vice President and National Director, Genetics and Genomics, Laboratory Corporation of America
2006-07 Senior Vice President, Corporate Development, Laboratory Corporation of America
2007- Executive Chairman, Signature Genomics Laboratories
2007- President and Chief Executive Officer, Cellpoint Diagnostics, Inc.

Awards, Honors and Invited Lectures:

1974 AB degree (History), Highest Honors
1979 James Tolbert Shipley Prize for best published research, Harvard Medical School
1979 Finalist, Soma Weiss Award, Harvard Medical School
1979 Finalist, Eastern Student Medical Association Research Awards
1979 Invited Paper, National Student Medical Association Research Awards
1980 Diplomat, National Board of Medical Examiners (202826)
1984 Diplomat and Board Certified, Clinical Geneticist, American Board of Medical Genetics
1985 Fellow, Leukemia Research Foundation
1985 Fellow, Oliver Wendell Holmes Society, Harvard Medical School

- 1985 Diplomat and Board Certified, American Board of Internal Medicine
- 1987 Invited speaker, "Ethical Issues in Genetic Screening and Gene Therapy",
Minority Biomedical Research Support Program Symposia, City College of New
York
- 1988 Invited speaker, "Non-molecular aspects of genetic screening", South African
Society of Human Genetics, Capetown, South Africa
- 1988 Invited address, "Social consequences of genetic screening", American Society of
Human Genetics (Social Issues Committee) New Orleans, LA
- 1989 Principal Speaker, "Are We Ready for the New Genetic Medicine?", Conference
at Harvard Medical School
- 1989 Principal Speaker, "Genetic Discrimination", Ehlers-Danlos National Conference,
Norfolk, Virginia
- 1990 Plenary Speaker, "Ghostbusting in Science: The Conduct and Context of
Biomedical Research", Colby-Bates-Bowdoin Conference on Biological Research
- 1990 Principal Speaker, "Ethical Issues in the Human Genome Initiative", American
Association of Clinical Pharmacy, San Francisco, CA
- 1991 Principal Speaker, "Genetics and the Bill of Rights", American Bar Association
National Conference on the Bicentennial of the 1991 Bill of Rights, Seattle, WA
- 1991 Speaker and Commissioned Paper, "The Scientific Basis of the 'Genetic
Revolution': A Selective Review" for AAAS-ABA Conference, Berkeley Springs,
West Virginia
- 1991 Session Chairperson, "Human Genome Research in The Interdependent World",
NIH/DOE sponsored conference, Bethesda, Maryland
- 1991 Distinguished Lecturer, Department of Energy/Oak Ridge National Laboratory
- 1991 Contributing Editor, "Journal Watch", New England Journal of Medicine/Mass.
Medical Society Publishing
- 1992 Invited Lecturer, Whitehead Institute/M.I.T., Sloan Foundation supported
presentation, Cambridge, MA
- 1992 Plenary Lecturer, Second International Conference on Bioethics, Fukui
University, Japan
- 1992 Plenary Lecturer, American Society of Human Genetics, San Francisco, CA
- 1992 Invited Lecturer, California Institute of Technology, Pasadena, CA
- 1993 Plenary Lecturer, ACLI/HIAA Symposium, Crystal City, Virginia
- 1993 Invited Speaker, N.I.H./D.O.E., ELSI Working Group, Bethesda, MD,
- 1993 Plenary Lecturer, George Mason University/T.I.G.R.. Inaugural Symposium,
Fairfax, Virginia
- 1993 Plenary Lecturer, National Society of Genetic Counselors, Atlanta, Georgia
- 1993 Plenary Lecturer, Japan Society for Bioethics, Tokyo, Japan
- 1993 Plenary Lecturer, 3rd International Symposium on Genetics, Fukui, Japan
- 1993 Founding Fellow, American College of Medical Genetics
- 1994 Plenary Lecturer, National Association of Insurance Commissioners, Washington DC
- 1994 Rose Lecturer, HealthEast, Minneapolis, MN
- 1994 Guest Lecturer, Wharton School of Business, University of Pennsylvania
- 1995 Plenary Lecturer, University of Maryland Invited Symposium, Wye, MD
- 1995 Plenary Lecturer, National Organization of Rare Disorders, Washington, DC
- 1995 Guest Lecturer, Wharton School of Business, University of Pennsylvania
- 1996 Plenary Lecturer, South Eastern Regional Genetics Group, Atlanta, GA

1996 Invited Speaker, World Affairs Council, Philadelphia, PA
1996 Invited Speaker, Cambridge Health Institute Symposium, San Francisco, CA
1996 Invited Speaker, N.I.H. Symposium on Cord Blood Stem Cells, Washington DC
1996 Invited Speaker, National Research Council, Woods Hole, MA
1996 Invited Speaker, Snowbird /University of Utah Conference, Snowbird, UT
1996 Invited Speaker, Tourette Syndrome Association of California, Ontario, CA
1996 Invited Speaker, Harvard University/Second Annual International Conference on Health and Human Rights, Cambridge, MA
1996 Plenary Lecturer, National Organization of Rare Disorders, Dallas, TX
1996 Plenary Lecturer, American Association of Cancer Research, Washington, DC
1996 Plenary Lecturer, Cooley’s Anemia Foundation CA Chapter, Pasadena, CA
1996 Plenary Lecturer, Council for Responsible Genetics, Patents and Commercialization Symposium, Cambridge, MA
1996 Invited Speaker, World Congress of Bioethics, San Francisco, CA
1996 Invited Speaker, Institute of Medicine, Washington, DC
1996 Invited Speaker, Food and Drug Administration, Washington, DC
1997 Special Contribution Award, Department of Veterans Affairs, Washington DC
1997 Invited Speaker, National Research Council, Washington, DC
1997 Plenary Lecturer, Huntington Disease Society of America/Northern California Chapter, Fremont, CA
1997 Plenary Lecturer, American Society of Clinical Pharmacy, Vancouver, Canada
1997 Scissors Award, Department of Veterans Affairs, Washington, DC
1997 Invited Speaker, UCSF Symposium on Cancer Epidemiology, San Francisco, CA
1997 Plenary Lecturer, Amyotrophic Lateral Sclerosis Foundation, Scottsdale, AZ
1997 Distinguished Lecturer, European Union/University of Zagreb, Zagreb, Croatia
1998 Plenary Speaker, North American Conference on Genetic Research and Native People, Poulson, MT
1998 Invited Participant, Case Western Reserve Stopping Science Symposium, Cleveland, OH
1998 Invited Speaker, Association for Employment Practices and Principles, San Francisco, CA
1998 Principal Speaker, UC Berkeley Germline Engineering Symposium, Berkeley, CA
1998 Plenary Lecturer, GeneCom Symposium, Adelaide, Australia
1998 Invited Speaker, SIGMA Xi, Vancouver, Canada
1998 Special Contribution Award, Department of Veterans Affairs, Washington, DC
1999- Distinguished Lecturer and Member, Sigma Xi Society
1999 Presenter, NIH/FDA Recombinant DNA Advisory Board, Washington, DC
1999 Featured Speaker, “Future Watch”, Harvey Mudd College, Claremont, Ca
1999 Plenary Speaker, “Genetics and Freedom”, Ministry of Justice, Valencia, Spain
1999 Invited Participant, “Stopping Science”, Case Western Reserve Medical School Cleveland, OH
1999 Invited Participant, “Genetics and the Law”, Arizona State University School of Law and SKB, Phoenix, AZ
1999 Speaker, “Genetic Discrimination Update”, National Conference of State Governments, Lake Tahoe, CA
1999 Special Session Speaker, “Genetic Discrimination”, Huntington’s Disease Society of America, Washington, DC

- 1999 Featured Speaker, Environmental Media Service's national news briefing, "Environmental Care", Washington, DC
- 1999 Invited Speaker, "Cloning", Calif. State Commission on Cloning, San Diego, CA
- 1999 Plenary Speaker, "Gene Patenting", IBC Conferences, Washington, DC
- 1999 Plenary Speaker, "Genetic Discrimination", National Conference of State Governments, Washington, DC
- 1999 Invited Lecturer, "Germline Gene Therapy", University of Louisville, Louisville, KY
- 1999 Speaker, "VISN Clinical Performance", Heart of Texas Medical Society, San Antonio, TX
- 1999 Invited Speaker, "VHA Clinical Policy", VHA Anesthesiologists National Meeting, Dallas, TX
- 1999 Invited Speaker, "VISN 17", Texas Association of Veterans Service Officers, Dallas, TX
- 1999 Featured Speaker, Environmental Media Service's national news briefing, "Food Safety", Washington, DC
- 1999 Special Session Speaker, "Genes and Violence Research", American Public Health Association, Chicago, IL
- 1999 Plenary Speaker, "Germline Gene Therapy". University of Basel and Schering Foundation, Berlin, Germany
- 1999-2000 Editor-in-Chief, GeneSage's GeneLetter
- 2000 Special Contribution Award, Department of Veterans Affairs
- 2000 Invited Speaker, 25th Anniversary of the Asilomar Conference, Asilomar, CA
- 2000 Featured Speaker, "Genomic Medicine", Biotechnology Center, Harvey Mudd College, Pomona CA
- 2000 Speaker, Society of Medical Anthropology, San Francisco, CA
- 2000 Plenary Speaker, "Genomics in Occupational Settings", Pitie-Salpetriere Hospital, Paris, France
- 2000 Featured Speaker, "Policy and Genomics", University of Essen, Germany
- 2000 Plenary Speaker, "Genomic Medicine", AAHP, Orlando, FL
- 2000 Invited Speaker, "Genetic Discrimination", ASLME, Cleveland, OH
- 2000 Featured Presenter, "The Next 20 Years", Palace of Fine Arts, San Francisco, CA
- 2000 Invited Speaker, "Technology in Medicine", ACHE Forum, Dallas, TX
- 2000 Plenary Speaker, "Genetics and Justice", 9th Circuit Conference, Sun Valley, ID
- 2000 Moderator, "The Genomic Revolution", NYU, New York City, NY
- 2000 Featured Speaker, "Genetic Testing", NSGC, Los Angeles, CA
- 2000 Invited Paper, "CF Testing and Coverages", BC/BS of California Technology Assessment Committee, San Bruno, CA
- 2000 Invited Presentation, "New Genetic Counseling", Mayo Clinic, Rochester, MN
- 2000 Invited Presentation, "Bioethics", International Society of Clinical Endocrinology, Sydney, Australia
- 2000 Presenter, "Genomics in Medicine", APHA, Boston, MA
- 2000 Invited Presentation, "Behavioral Genetics and Responsibility", Reno Commission on DNA Technologies and Identification, Cambridge, MA
- 2000 Luncheon Speaker, "Update on DNA", 9th Circuit Federal Judges, San Francisco, CA
- 2001-2001 Fellow, American College of Physicians
- 2001 Plenary Presentation, "Living with the Genome", Wash. State Health Dept., Tacoma, WA

- 2001 Presenter, "Genomic Medicine", Council of the Medical Service, AMA, Chicago, IL
- 2001 Program Organizer, "Genomic Medicine", AAHP Leadership Board, Del Mar, CA
- 2001 Featured Speaker, "New Genomics", IBC International Inc, San Diego, CA
- 2001 Session Chair, "Personalized Medicine", Cambridge Health Institute, Inc. San Francisco, CA
- 2001 Featured Speaker, "Unbounded Thinkers", Webb School of CA, Claremont, CA
- 2001 Grand Rounds, "Personalized Medicine", Cedars-Sinai Hospital, Beverly Hills, CA
- 2001 Plenary Panel, "Toxic Torts and Genomics", ABA Section, San Francisco, CA
- 2001 Panel Leader, "Biodevastation and GMOs", International Biodevastation Conference, San Diego, CA
- 2001 Rose Lecturer, "Genomic Medicine", ING Insurance Company, Minneapolis, MN
- 2001 Panelist, "Stem Cells", Health Technology Center, Inc. San Francisco, CA
- 2001 Featured Speaker, "Genomic Entrepreneurship", Bay Area Business Breakfast Forum, San Francisco, CA
- 2001 Panelist, "Genetic Testing", Health Technology Center, Inc., San Francisco, CA
- 2001 Panelist, "Genetic Discrimination", NCSL National Meeting, Washington, DC
- 2001 Plenary Speaker, "Predictive Medicine", North American Primary Care Research Group Annual Meeting, Nova Scotia, Canada
- 2001 Panelist, "Research Compliance", Health Care Compliance Assoc., Anaheim, CA
- 2001 Invitee, "Genomic Medicine and Curriculum Reform", AMA, Chicago, IL
- 2001 Plenary Speaker, "Human Cloning", AHRP Annual Meeting, Washington, DC
- 2002 Session Chair, "Personalized Medicine", IBC International Inc. San Francisco, CA
- 2002 Panelist, "Genetic Discrimination", NIH/West Harlem Environmental Action Program, Columbia University, New York City, NY
- 2002 Featured Panelist, "Genomic Medicine", Grant Makers on Health Annual Meeting, New York City, NY
- 2002 Invited Participant, "Living with the Genie: Governing Science and Technology in the 21st Century", Columbia University, New York City, NY
- 2002 Featured Panelist, "Pharmacogenomics", AMA Leadership Meeting, Los Angeles, CA
- 2002 Featured Speaker, "Personalized Medicine", Board of Directors, California Health Care Foundation, Dana Point, CA
- 2002 Dinner Speaker, "Stem Cells", Milwaukee OB/Gyn Society, Milwaukee, WI
- 2002 Featured Speaker, "Genetic Discrimination", Whittier Law School, Whittier, CA
- 2002 Lorene T. and Floyd Davidson Lecturer in Biology, Baylor University, Waco, TX
- 2002 Featured Speaker, "Clinical Uses of Stem Cells", ACOG Annual Meeting, Los Angeles, CA
- 2002 Selected Invitee, "Pharmacogenomics", ATKearney Conference, Venice, Italy
- 2002 Selected Participant, "Genomics, Science and the Media", Institute Pasteur, Paris, France
- 2002 Rose Lecturer, "Personalized Medicine", ING Insurance Group, Minneapolis, MN.
- 2003 Plenary Speaker, "Stem Cells", Merck Inc. National Sales Meeting, San Antonio, TX
- 2003 Invited Lecturer, "Personalized Medicine: Will It Work?" Laboratory Corporation of America, Burlington, NC
- 2003 Featured Program Presenter, "Problems with Genomic Medicine Delivery", BIO Annual National Meeting, New York City, NY

- 2003 Grand Rounds Presenter, “Stem Cells: Making the Promise a Reality”, Yale University OB/GYN Grand Rounds, New Haven, CT.
- 2003 First Plenary Session Speaker, “The Ethics of Gene Therapy”, Second International Symposium on Molecular Diagnostics and Skin Therapy, University of Düsseldorf, Düsseldorf, Germany
- 2003 Invited Participant, “Ethics and Technology”, University of California, Berkeley, CA
- 2003 Grand Rounds Presenter, “Stem Cells: Promise and Problems in Delivery”, OB/GYN Grand Rounds, Stanford University Medical Center, Stanford, CA
- 2003 Presenter, “Stem Cells”, 7th Annual Update on Perinatal Issues, Overlake Medical Center, Bellevue, WA
- 2003 Invited Participant, “Risk in Biotechnology”, Hybrid Vigor Institute, San Francisco, CA
- 2003 Invited Participant, “Genomics and Ethics”, University of Colorado Annual CME, Aspen, CO
- 2003 Lecturer, “Maladaptation”, Anthropology Course Number 1, University of California, Berkeley, CA
- 2000-03 Distinguished Lecturer, Sigma Xi Society. During this period delivered 30-40 talks, “Promise and Pitfalls of the Genomic Revolution” and “Legislating the Genome: Public Policy and Biotechnology”, at universities and colleges around the country.
- 2004 Presenter, “Tests, Healthcare and Rights in the Post Genomic World”, The Council for Responsible Genetics, San Francisco, CA
- 2005 Presenter, “Genetic Screening and Pediatric Testing, The Hastings Center, Garrison, NY
- 2005 Presenter, “Business Stakeholder Perspectives on the Introduction of DX/RX Combinations, IBC/Molecular Diagnostics and Personalized Medicine Conference, San Francisco, CA
- 2005 Presenter, “Molecular Diagnostics – Today and Tomorrow”, California Clinical Lab Association, Sacramento, CA
- 2006 Presenter, “Legislating the Genome: Making a good world of genomics”, University of Connecticut School of Medicine, Farmington, CT
- 2006 Presenter, “Challenges and Opportunities in the Diagnostics Industry”, Duke University Healthcare Sector Group, Durham, NC
- 2006 Presenter, “Academic/Commercial Collaborations in Diagnostics: The Duke/LabCorp Model”, Tampa G2 Conference, Tampa, FL
- 2006 Presenter, “Update on Pharmacogenomics”, ACSP Annual Meeting, Las Vegas, NV
- 2007 Presenter, “A Discussion on Companion Diagnostics and its Role in the Future of Healthcare”, Lazard Healthcare Conference, New York, NY
- 2007 Presenter, “Looking Beyond the Horizon in Laboratory Science, Clinical Laboratory Management Association, Murphys, CA
- 2007 Presenter, “Development of Diagnostics for the Metabolic Syndrome: Trends, Risk Factor, Interactions and Future Direction, IBC Life Sciences, Boston, MA
- 2007 Presenter, “Diagnostics in Personalized Medicine”, Personalized Medicine Meeting, San Francisco, CA
- 2008 Presenter, “Diagnostics in Translation: A Challenge to Value”, Molecular Medicine Tri-Conference, San Francisco, CA

Governmental Committees, Contracts, Consultantships and Boards:

- 1989 Contractor, Office of Technology Assessment, United States Congress, "Genetic Testing in the Workplace"
- 1989 Reviewer, Office of Technology Assessment, United States Congress, "DNA Identification Systems"
- 1989 Special N.I.H. Study Section, "The Human Genome Initiative"
- 1990 Reviewer, Office of Technology Assessment, United States Congress, "Genetic Testing in the Workplace"
- 1990 Board of Directors, Science for the People
- 1990-93 Scientific Advisor, Council for Responsible Genetics
- 1990- Advisory Board, CMT International.
- 1990-97 Consultant, State of California, Northern California Regional Centers
- 1991-96 Member, Scientific Advisory Board, Genetrix Corporation.
- 1991-93 Member, Special Insurance Task Force on Insurance and Genetics, NIH/DOE Human Genome Initiative.
- 1991-95 Consultant, Assembly and Senate, State of California, Sacramento, CA
- 1991 Member, Study Section on Cystic Fibrosis Screening, NIH Genome Center
- 1991 Reviewer, Office of Technology Assessment, United States Congress, "CF Screening".
- 1991-93 Chairperson, Subcommittee on "Genetic Discrimination", NIH Special Task Force on Insurance and Genetic Information.
- 1992 Consultant, Institute of Medicine's Committee of Assessing Genetic Risks
- 1993-97 Member, Social Issues Committee, American Society of Human Genetics.
- 1993- Director, Council for Responsible Genetics, Cambridge, MA.
- 1994 Reviewer, Office of Technology Assessment, United States Congress "DNA Patenting"
- 1994- Consultant, National Association of Insurance Commissioners
- 1994-00 Director, Genethics Center, Hagerstown, Maryland.
- 1994-97 Director, Monterey Regional Health, Inc., Monterey, CA
- 1995- Consultant, California Senate Select Committee on Genetics and Public Policy
- 1995-98 President and CEO, International Cord Blood Foundation
- 1995- Chair, Medical/Scientific Advisory Board, Cord Blood Registry, Inc.
- 1995 Consultant, Sequana, Inc.
- 1996 Consultant, Institute of Medicine Committee on Mental Diseases
- 1996- Director, Cardiac Arrhythmia Research and Education Foundation
- 1996-98 Director, California Biotechnology Action Coalition
- 1996 Consultant, National Research Council's Computer Science and Telecommunications Board
- 1996 Consultant, Sandoz, Inc.
- 1997 Consultant, Arcades Biosystems, Inc.
- 1997 Consultant, SmithKline Beecham Pharmaceuticals, Inc.
- 1997-99 Member, Scientific Advisory Board, Benelytics, Inc.
- 1997 Consultant, National Research Council's Board on Biology
- 1997-00 Member, National Leadership Board, Veterans Health Administration
- 1997-00 Member, National Bioethics Committee, Veterans Health Administration

1997-00 Member, National Technology Review Panel, Veterans Health Administration
1997-00 Reviewer, Health Services Research and Development Program, Veterans Health Administration
1998 Member, National Emergency Care Task Group, Veterans Health Administration
1998 Chairperson, National Committee on External Appeals, Veterans Health Administration
1998 Member, National Task Group on Viagra, Veterans Health Administration
1998 Reviewer, United States President's National Bioethics Advisory Commission
1998- Director, Cord Blood Donor Foundation
1998-03 Founder and Treasurer, GeneSage, Inc.
1998-00 Member, Research and Methods Committee, Quality Enhancement Research Enhancement Initiative, Veterans Health Administration
1998-00 Chairperson, National Committee on Internal Appeals, Veterans Health Administration
1998-00 Member, VHA HSR&D Liaison Committee
1998-00 Member, VHA Quality Evaluation and Research Initiative Research and Methodology Committee
1998-00 Member, Veterans Evidence-based Research Steering Committee
1998-00 Member, VHA Health Economics Center Steering Committee
1998-00 Member, VHA Cardiology and Cardiac Surgery Improvement Program Steering Committee
1998-99 Chair, VHA Bioethics Subcommittee on Use of Unapproved Therapies
1998- Chair, Medical Advisory Board, Cord Blood Registry, Inc.
1999 Consultant, NIH/FDA Recombinant DNA Advisory Committee
1999-00 Member, VHA Customer Service Advisory Board
1999 Member, VHA Clinical Managers Hepatitis C Task Group
1999 Member, VHA Clinical Managers Complementary and Alternative Medicine Task Group
1999-00 Member, VHA Telecommunications Advisory Committee
1999-00 Member, Veterans Health Initiative Steering Committee
2000-04 Consultant, XOMA Corporation
2001-03 Member, Alpha-1 Foundation, Consumer Issues Advisory Committee
2002-04 Consultant, Celera Diagnostics, Inc., Alameda, CA
2002-04 Consultant, Sequenom, Inc., San Diego, CA
2002- Affiliate, Institute for the Future, Inc., San Francisco, CA
2002-04 Consultant, Health Tech, Inc., San Francisco, CA
2002 Consultant, NorthBay Health Care, Inc., Bay Point, CA
2002-03 President and Chairman, Alpha-1 Association, Minneapolis, MN
2002-06 Board Chairman, Council for Responsible Genetics, Cambridge, MA
2007- Director, Bioscale, Cambridge, MA
2007- Director, Blue Shield Foundation of California, Translating Personalized Medicine to Practice and Policy: Moving the Policy Agenda Forward
2008- Director, Cytellect, Inc., San Diego, CA
2008- Director, Cellpoint Diagnostics, Mountain View, CA
2008- Director, KidsDx, San Francisco, CA
2008- Director, Lipomics, West Sacramento, CA

- 2007- Board Member, Secretary's Advisory Committee on Genetics, Health and Society, Bethesda, MD (Pending)
- 2007- Advisor, National Institute of Dental and Craniofacial Research, Bethesda, MD (Pending)
- 2007- Director, Signature Genomics, LLC, Spokane, WA
- 2008- Member, VA Genomic Advisory Board, Washington, DC (Pending)

Professional Societies (Past and Current):

American Federation of Clinical Research, American Association for the Advancement of Science, American College of Medical Genetics, American Society of Human Genetics, Genetics Society of America, Human Genome Organization (HUGO), Physicians for Social Responsibility, New York Academy of Science, American College of Physicians, European Society for Human Genetics, Sigma Xi Science Society, Chief Medical Officers Society, Hemophilia Association of America.

Major Research Interests:

The impact of genomic information and biotechnology on society.

The integration of genomics in to health care. Post-genomic health and identity.

Molecular biology and immunogenetics, its relationship to cellular differentiation, and its application to cancer care.

Human stem cell research and its relationship to clinical medicine.

Grants:

- 1985-86 Fellowship, Leukemia Research Foundation
- 1986-88 Supported by core funds, Dana Farber Cancer Institute
- 1988-90 Supported by New England Deaconess Hospital and private grants to the Clinic for Inherited Diseases
- 1989 March of Dimes Grant No. 4-220, "The New Genetic Medicine"
- 1989-90 Combined Harvard Medical Genetics Training Program (American Board of Medical Genetics, Inc.)
- 1991 P.I., "Bioscience and Society: The Impact of the Human Genome Initiative", \$30,000, DOE#DE-AC03-76SF00098
- 1991-93 Co-P.I., "Studies on Genetic Discrimination", DOE Contract, \$150,000/1.5 years, DOE#DE-FG02-92ER61395
- 1991-93 Co-PI "Vitamin C and Lung Cancer", C.C.O.P. (multicenter trial), NIH/M.D. Anderson
- 1991-93 Consultant "Cystic Fibrosis Testing and Families", NIH, \$130,000/2 years, (total grant support), NIH#1-R01-HG00639-01

- 1991-92 Consultant "CF and HbS Screening", NIH, \$298,000/3 years (total grant support), NIH#DE-FG03-92ER6-1393
- 1992-93 P.I., "Indepth Studies of Genetic Discrimination, NIH, \$9,500, NIH#263-MD-245650
- 1992-94 P.I./Supervisor, Post Doctoral Fellowship (Vicki Laden), "Legal Studies of Genetic Discrimination", NIH#1 F32 HG00086-01
- 1993-94 Supervisor, Post Doctoral Fellowship (Dr. Mildred Cho), "Studies in Biotechnology", Center for Health Care Evaluation, UCSF and Stanford Universities.
- 2000- Subcontractor, "CED- Distance Learning", HRSA Grant No. 7T02MC00021 Charles Hamad, PhD and Phil Reilly, MD, JD PIs (\$25,000)
- 2001-2 Contractor, "Non-Health Care Uses of Genomic Information", commissioned project for Sequenom, Inc (\$54,000)
- 2002 Principal Investigator, "Genomic Medicine for Health Care Decision Makers" (Wendy Everett, Co-PI) with the Institute for the Future, from Robert Wood Johnson Foundation (\$132,000)
- 2003 Principal Investigator, "Genetic Information and the Law: Establishing a Comprehensive Database of Essential Cases and Regulations" with the Council for Responsible Genetics from the Robert Wood Johnson Foundation (\$130,090)

Teaching Experience:

- 1981-82 Resident, University of Washington Affiliated Hospitals
- 1982-84 Fellow, Division of Medical Genetics, Department of Medicine, University of Washington, Seattle
- 1984 Acting Assistant Professor, Department of Genetics, University of Washington
- 1984-90 Tutor, "Life Cycle", Harvard Medical School
- 1988 Tutor, "Identity, Defense, and Microbes", Harvard Medical School
- 1988-90 Tutor, "Genetics", Harvard Medical School
- 1990-97 Teaching Attending, San Francisco General Hospital, UCSF
- 1990-97 Teaching Attending, California Pacific Medical Center
- 1993-97 Teaching Attending, VAMC, Palo Alto and Stanford University Medical School
- 2000-02 Visiting Professor, Department of Anthropology, University of California at Berkeley, Anthropology 112, "Genetics and Society"
- 2003- Adjunct Professor, Department of Anthropology, University of California at Berkeley

PUBLICATIONS:

1. Kagnoff M, Billings P and Cohn M. Functional characteristics of Peyer's Patch lymphoid tissue. *J Exp Med* 1974; **139**:407.
2. Billings P, Burakoff S, Dorf M, and Benacerraf B. Cytotoxic T lymphocytes specific for I region determinants do not require interaction with H-2K or D gene products. *J Exp Med* 1977; **145**:1387.

3. Billings P, Burakoff S, Dorf M and Benacerraf B. Cytotoxic T lymphocytes induced allogeneic I region determinants react with Ia molecules on trinitrophenyl-conjugated syngeneic target cells. *J Exp Med* 1977; **146**:623.
4. Billings P, Burakoff S, Dorf M, and Benacerraf B. Genetic control of cytolytic T lymphocyte responses. I. Gene control of the specificity of cytolytic T lymphocyte responses to trinitrophenyl-modified syngeneic cells. *J Exp Med* 1978; **148**:341.
5. Billings P, Burakoff S, Dorf M and Benacerraf B. Genetic control of cytolytic T lymphocyte responses. II. The role of the host genotype in parental-F1 radiation chimeras in the control of specificity of cytolytic T lymphocyte responses to trinitrophenyl-modified syngeneic cells. *J Exp Med* 1978; **148**:253.
6. Burakoff S, Riccio J, Billings P, Benacerraf B, and Dorf M. Genetic control of cytolytic T lymphocyte responses. III. The role of K and I region alleles on the specificity of cytolytic T lymphocytes responses to trinitrophenyl-modified syngeneic cells. 1980. *J Immunol* 1980; **125**:1432.
7. Billings P and Bernstein M. Physicians poor at prevalence and positive predictive value. *JAMA* 1985; **254**:1173 (letter).
8. Billings P. Amiloride in the treatment of lithium induced diabetes insipidus. *N Engl J Med* 1985; **312**:1575 (letter).
9. Billings P. Hypercoagulability, hyperlipidemia and serum antiproteases. *Ann Intern Med* 1985; **102**:724 (letter).
10. Billings P. Ventricular thrombus and hyperaggregable platelets. *Amer J Med Sci* 1985; **289**(6):223 (letter).
11. Billings P. Mitral valve prolapse requiring surgery. *Am J Med* 1985; **79**(11):A62 (letter).
12. Billings P and Bernstein M. Re: Predictive value of a positive test. *JAMA* 1986; **255**:1437 (letter).
13. Billings P. Genetic links say little for the complexity of diseases. *Los Angeles Times* (syndicated) 1987; Part II:5 (3/18/87).
14. Motulsky AG, Burke W, Billings P, and Ward RH. Hypertension and the genetics of red cell membrane abnormalities. In: Molecular approaches to human polygenic disease (Ciba Foundation Symposium 130). *Wiley* 1987; 150-66.
15. Burd P, Freeman G, Wilson S, Billings P, Berman M, DeKruyff R, and Dorf M. Cloning and Characterization of a novel T-cell activation gene. *J Immunol* 1987; **139**:3126-3132.

16. Billings P. Preventing tampering with prescriptions: The Marton Method. *Ann Intern Med* 1988; **105**:637 (letter).
17. Burd P, Rollins B, Wilson S, Billings P, Stiles C, and Dorf M. Comparison of Fibroblast and T-Cell Activation Genes. *Cell Immunol* 1988; **115**:481-3.
18. Wilson S, Burd P, Billings P, Martin C, and Dorf M. The Expression and Regulation of a Potential Lymphokine Gene (TCA3) in CD4 and CD8 T-Cell Clones. *J Immunol* 1988; **141**(5):1563-70.
19. Kuchroo V, Steele J, Billings P, Selvaraj P, and Dorf M. Expression of CD3 Associated Antigen Binding Receptors on Suppressor T Cells. *PNAS* 1988; **85**(12):9209-13.
20. Billings P. The Biology of Cancer. *SFTP* 1989; **21**(1):10-1.
21. Billings P. Debunking the Genetic Myth. *Technology Review* 1989; **6**:75-6.
22. Billings P. Responsible Genetics? *Cell* 1989; **59**:12-3.
23. Billings P. Transfusions and the Acquired Immunodeficiency Syndrome. *Ann Intern Med* 1989; **111**:768 (letter).
24. Billings P. Viewpoint: The Consequences of Genetic Testing. *Clin Chem News* 1989; **12**:5.
25. Wilson SD, Billings P, D'Eustachio P, Fournier RK, Geissler E, Lalley PA, Burd PR, Housman D, Taylor B and Dorf ME. Clustering of Cytokine Genes on Mouse Chromosome 11. *J Exp Med* 1990; **171**:1301-14.
26. Billings P. Genetic Discrimination. *Gene Watch* 1990; **6**(4-5):7,15.
27. Billings P. Brewing Genes and Behavior: The Potential Consequences of Genetic Screening for Alcoholism. In: Banbury Conference 33: The Molecular Biology and Genetics of Alcoholism. *Cold Spr Harbor Pubs* 1990; **33**:333-50.
28. Billings P. Mutational Analysis in Cystic Fibrosis. *N Engl J Med* 1990; **323**(1):62-3 (letter).
29. Billings P. Alert on Genetic Discrimination. *Medical Tribune* 1990; **31**(12):15.
30. Kuchroo V, Billings P, Levin C, Martin C, Kubo R, and Dorf ME. Antigen specific and antibody mediated growth inhibition of suppresser T-cell hybridomas: Roles of H-2 and the CD3-TcR complex. *J Immunol* 1990; **145**(4):1059-65.
31. Billings P. Labels Increase Burdens of Afflicted. *Currents* 1990; **Summer**:13.
32. Billings P. Promotion of the Human Genome Project. *Science* 1990; **250**:1071 (letter).

33. Billings P. Biotechnology: Ethical Dilemmas. *Biotech Monitor* 1991; **1**(2):2,4-6. .
34. Billings P, Smith C, and Cantor C. New Techniques in the Physical Mapping of the Human Genome. *FASEB J* 1991; **5**(1):28-34.
35. Billings P. The Context of Genetic Screening. *Yale J Med* 1991; **64**:47-52.
36. Billings P. Beware of Insurers Offering Tests. *SF Examiner* July 17, 1991; Part A:17.
37. Billings P. Rising Cost of Private Health Insurance. U.S. Congress Committee on Energy and Commerce. *US Government Printing Office* 1991; 11-58.
38. Billings P. How Many Genetic Diseases? *Lancet* 1991; **338**:1603-4 (letter).
39. Billings P, Kohn M, DeCuevas M, Beckwith J, Alper J and Natowitz, M. Discrimination as a Consequence of Genetic Testing. *Am J Hum Genet* 1992; 50:476-482.
40. Billings P and Beckwith J. Genetic Testing in the Workplace. *Trends in Genetics* 1992; **8**(6):198-202.
41. Billings P. Causes of Discrimination in Health. *GeneWatch* 1992; **7**(6): 2-3.
42. Billings P. The Scientific Basis of the "Genetic Revolution": A Selective Review. In: The Genome, Ethics and the Law: Issues in Genetic Testing. A.A.A.S. *Pubs.* 1992: 23-45.
43. Billings P. Privacy Violations Arising From Genetic Discrimination: Informing and Limiting The Human Genome Initiative. Testimony before the United States House of Representatives. *US Government Printing Office* 1992: 242-251.
44. Billings P, Beckwith J, and Alper J. The Genetic Analysis of Human Behavior: A New Era. *Soc Sci Med* 1992; **35**(3): 227-238.
45. Billings P. But Is He Genetically Diseased?--Commentary. *Hastings Center Report* 1992; **22**(4):18-19 (Suppl).
46. Billings P, Alper J, Beckwith J, Barash C, and Natowicz M. Definition and Implication of Genetic Discrimination. *Am J Hum Genet* 1992; **51**(4) 903-905 (letter).
47. Billings P. International Aspects of Genetic Discrimination. In: Human Genome Research and Society. *Eubios Ethics Institute* 1992; 114-117.
48. Billings P, Lippman A, and Wilker, N. Conflicts, Ethics and the Genome. *Am J Hum Genet* 1992; **51**(5) 1168-9 (letter).
49. Billings P. Applications of DNA Fingerprinting. *J Peds* 1992; **121**(6): 989 (letter).

50. Billings, P. Genetic Testing in the United States: A Brave New World? Testimony before the Subcommittee on Human Resources and Intergovernmental Relations, United States House of Representatives. *US Government Printing Office* 1992.
51. Billings P. Academic Freedom. *GeneWatch* 1992; **8**(4): 1-2.
52. Billings P. Gene Technology: Views of its Criminal Justice Applications. In: DNA on Trial: Genetic Identification and Criminal Justice. *Cold Spr Harbor Pubs* 1992; 1-4.
53. Wilker N, Stawski S, Lewontin R and Billings P. DNA Data Banking and the Public Interest. In: DNA on Trial: Genetic Identification and Criminal Justice. *Cold Spr Harbor Pubs* 1992; 141-149.
54. Laden V and Billings P. ERISA after Greenberg v. H & H Music Co.: Limiting Predictive Genetic Testing and the Benefits of the Human Genome Project. Background Paper. Joint NIH-DOE Task Force on Genetic Information and Insurance. *NCHGR* 1992.
55. Billings P. Genetics and Insurance Discrimination. In: Advances in Genetic Information: A Guide for State Policy Makers. Brown and Markshall (eds). *Council of State Governments* 1992: 43-56.
56. Billings P. Public Must Be Educated About the Limited Predictive Usefulness of Genetic Diagnoses. *Genetic Engineering News* 1992; **12**(19): 4, 38.
57. Billings P. Genetic Discrimination: State Legislative Update. *The Genetic Resource* 1992; **6**(2): 80.
58. Billings P. Promises and Pitfalls of Genetic Testing. *Bay Area BioScience Reports* 1992;**3**(4): 5,7.
59. Billings P. Not My Problem. *Hastings Center Report* 1993; **23**(1): 46 (letter).
60. Billings P. Technological Imperatives and Conflicts of Interest: Their Impact on the "New Genetics" and Medicine (background paper). For: Assessing Genetic Risks. *National Academy Press* 1993.
61. Billings P. and Beckwith J. Born Gay? *Technology Review* 1993; **96**(5): 60-2.
62. Billings P. Freedom and The New Genetics. *Proceedings of the BBV Foundation* May, 1993.
63. Billings P. Genetic Discrimination, *Healthcare Forum Journal* 1993; **36**(5): 35-7.
64. Billings P. Genetic Discrimination by Insurers: The Public Perception. *J Insur Med* 1993; **25**(2): 184-91.

65. Billings P. Genetic Discrimination: What Can We Learn from History? (commentary) Blatt, Miller and Haddow (eds). *The Genetic Resource* 1994; **8**(1): 44.
66. Billings P, Barash C, Geller L, and Alper J. The Context of Hemochromatosis Screening. *New Eng. J. Med.* 1993; **329**(27): 2037 (letter).
67. Billings P. The Gay Gene: A New Fish Story? *SF Examiner*. August 1, 1993; Part A:17.
68. Billings P. A Study of Genetic Discrimination. (background paper and appendix). In: Genetic Information and Health Insurance: Report of the Task Force on Genetic Information and Insurance. *NIH Publication* 93-3686 1993.
69. Levine B. and Billings P. Genetic Discrimination and the Workplace. *Forum Appl Res and Pub Pol* 1994; **Fall**: 132.
70. Billings P, Lippman A, Bereano P, Gracey C, Henifin M, Hubbard R, Krimsky S, Lewontin R, Messing K, Newman S, Norsisian J, Saxton M, Stabinsky D, and Wilker N. Position Paper on Human Germ Line Manipulation. *Human Gene Therapy* 1993; **4**:35-7.
71. Billings P. Comments on genetic research and discrimination in mental illnesses. In: Mental Disorders and Genetics: Bridging the Gap Between Research and Society. *US Government Printing Office* 1994
72. Billings P. Genetic Information in The Healthcare Reform Era. In: Bioethics for the People by the People. *Eubios Ethics Institute* 1994; 51-56.
73. Billings P. and Hubbard R. Fragile X Testing: Who Benefits? *GeneWatch* 1994; **9**(3-4):1-3.
74. Billings P. and Hubbard R. Relevance of Fragile X Diagnosis Not Well-Established. *GeneWatch* 1994; **9**(3-4):3.
75. Billings P. Genetic Discrimination and Behavioral Genetics: The Analysis of Sexual Orientation. *Eubios Ethics Institute* 1994; 35-39.
76. Alper J, Billings P, Barash C, Geller L, and Natowicz M. Genetic Discrimination and Screening for Hemochromatosis. *J Pub Health Policy* 1994; **15**(3): 345-358.
77. Billings P. Preface to Paperback Edition: Justice and the Prosecutor's Fallacy. In: DNA on Trial: Genetic Identification and Criminal Justice. Billings P (ed). *Cold Spr Harbor Pubs* 1994; vii-viii.
78. Billings P. Legislation Regulating Insurance Uses of Genetic Testing. Testimony before the United States House of Representatives. *US Government Printing Office* 1994.

79. Billings P, Kohn M, DeCuevas M, Beckwith J, Alper J and Natowitz, M. Discrimination as a Consequence of Genetic Testing. In: Contemporary Issues in Bioethics (4th Edition). Beauchamp T and Walters L (eds) *Wadsworth*, Belmont, California 1994: 637-643.
80. Billings P. DNA on trial. *N Engl J Med* 1995; **333**(9): 602 (letter).
81. Billings P. Paradise Lost: Discrimination Using Genetic Information. In: Proceedings of the Symposium on Critical Choices. Engel JV (ed) *University of Toronto Press* 1995.
82. Stone AR with Billings P. Genetics/Technology/Sexuality Perspective. Allucquere Rosanne Stone speaks to Paul Billings. Commissioned paper for Italian national television productions, 1996.
83. Geller L, Alper J, Billings P, Barash C, Beckwith J and Natowicz M. Individual, Family, and Societal Dimensions of Genetic Discrimination: A Case Study Analysis. *Sci Eng Ethics* 1996; **2**(1):71-88.
84. Billings P. The Health Scene: Beltway Reveries. *J Am Diab Assoc* (on-line) 1996; **1**:1.
85. Billings P. and Pelias M. Disclosure of research results of medical interest: points to consider (background paper). For: the Social Issues Committee, American Society of Human Genetics. 1996.
86. Billings P. Comments on the social, legal and policy issues arising from the genetic revolution. Testimony before the Senate Select Committee on Genetics and Public Policy on April 8, 1996. *State of California Printing Office* 1996.
87. Billings P. DNA on trial: insights in application. Testimony before the Senate Select Committee on Genetics and Public Policy on May 9, 1996. *State of California Printing Office* 1996.
88. Beall T. with Billings P. 10 minutes with Paul Billings, MD. *Calif Phys* 1997; **5**:22-4.
89. Cho M. and Billings P. Conflict of interest and institutional review boards. *J Invest Med* 1997; **45**(4): 154-9.
90. Billings P. Comments on human cloning. Testimony before the Senate Select Committee on Genetics and Public Policy on April 9, 1997. *State of California Printing Office* 1997.
91. Billings P. Genetic information and privacy (a background paper). For: For the Record: Protecting Electronic Health Information. *National Academy Press* 1997.
92. Billings P. Senate Bill 654: comments on genetic discrimination in employment. Testimony before the Judiciary Committee of the Senate of the State of California on April 8, 1997. *State of California Printing Office* 1997.

93. Verma I (moderator), Billings P, Cole-Turner R, Glorioso J, Lemoine N, Miller A, and Salusky J. Medince as mutagen: A debate. *HMS Beagle: The BioMedNet Magazine* 1998; **42**; Nov 13 (<http://www.wiomednet.com/hmsbeagle/40/cutedge/synopsis.htm>).
94. Billings P. Comments on genetic research and privacy issues. In: Privacy Issues in Biomedical and Clinical Research. *National Academy Press* 1998.
95. Koenig B, Greely H, McConnell L, Silverberg H, Raffin T, Billings P, and Members of the Breast Cancer Working Group of the Stanford Program in Genomics, Ethics and Society. Genetic testing for BRCA1 and BRCA2: Recommendations of the Stanford Program in Genomics, Ethics, and Society. *J Women's Health* 1998; **7**(5):531-45.
96. Billings P. Wider impact? *HMS Beagle: The BioMedNet Magazine* 1998; **42**; Nov 13 (http://www.wiomednet.com/hmsbeagle/42/people/letters.htm#ed_note) (letter).
97. Norsigian J, Whelan S, and Billings P. Privacy and medical-records research. *N Engl J Med* 1998; **338**(15): 1076 (letter).
98. Billings P. The hereditarian myth in the genetic age. In: Proceedings of the North American Conference on Genetic Research and Native People (Eds. Harry D and Gobert J) 1998 .
99. Billings P. Limitations of Human Genome Project. In: 1998 Sigma Xi Proceedings: International Cooperation in Science and Technology. (Ed. Reid R) 1999; pp 87-93.
100. Billings P. Genoculture and the Human Genome Project. In: Proceedings of the First Annual GeneCom Conference. (ed. Webber G) 1998.
101. Billings P and Newman S. Crossing the germline. *GeneWatch* 1998; **11**(5-6):1-4.
102. Billings P. Germline culture: the genetics of hubris. In: Engineering the Human Germline. (ed. Stock G and Campbell J) Oxford University Press 2000.
103. Billings P. The limits of intervention. In: Proceedings of the UCLA conference on germline modification. (ed. Stock G) 1999.
104. Billings P. *In utero* gene therapy: the case against. *Nature Med* 1999; **5**(3):255-6.
105. Billings P. DNA data banks would taint justice. *Boston Globe* 1999; Jan 14 (A):19.
106. Billings P. Iceland, blood and the role of science. *Am Sci* 1999; **87**(3):199-00..
107. Billings P, Newman S, and Hubbard R. Human germline gene modification: a dissent. *Lancet* 1999; **353**:1873-5.
108. Billings P. Perspective on medicine: does life as a patient begin even before patient is born? *Los Angeles Times* 1999; Mar 11 (B):9.

109. Billings P. Comments on DNA databases. In: DNA Databases: does expanding them threaten civil liberties? (Colin T, editor) *CQ Researcher* 1999; **9**(20):449-72.
110. Billings P. Modified foods are like drugs. *Boston Globe* 1999; **Aug 28** (A):19.
111. Nadar C, Herbert M, Billings P, Bereano P, Hubbard R, King J, Newman S, and Stabinsky D. Resdesigning Evolution? *Science* 1999; **285** (3):1491 (letter).
112. Billings P. Applying Advances in Genetic Medicine. *HealthPlan* 2000; **Nov/Dec(4)**:32-5.
113. Billings P. Lessons from genetic discrimination. *Genetics in Medicine* 2000; **2**(4):207-8s
114. Billings P. Homecooked eugenics. *GeneLetter* 2000; **1**(Feb; 1): www.geneletter.com
115. Billings P. New heights of compatibility. *GeneLetter* 2000; **1**(Feb; 1): www.geneletter.com
116. Billings P. Understanding the EEC split. *GeneLetter* 2000; **1**(Feb; 1): www.geneletter.com
117. Billings P. Thinking in neurofibromatosis type 1. *GeneLetter* 2000; **1**(Feb; 1): www.geneletter.com
118. Billings P. Constructing a new genetics. *GeneLetter* 2000; **1**(Feb; 1): www.geneletter.com
119. Billings P. Wherefore art thou disease genes? *GeneLetter* 2000; **1**(Mar; 2): www.geneletter.com
120. Billings P. Genetic for all. *GeneLetter* 2000; **1**(Apr; 3): www.geneletter.com
121. Billings P. Following up. *GeneLetter* 2000; **1**(May; 4): www.geneletter.com
122. Billings P. A gene therapy death. *GeneLetter* 2000; **1**(Jun; 5): www.geneletter.com
123. Billings P. Gene therapists beware: lessons from GM food. *GeneLetter* 2000; **1**(Jun; 5): www.geneletter.com
124. Billings P. Mutation: the good, the bad and the ugly. *GeneLetter* 2000; **1**(Jul; 6): www.geneletter.com
125. Billings P. Biotechnology's albatross. *GeneLetter* 2000; **1**(Aug; 7): www.geneletter.com
126. Billings P. A genomic failure. *GeneLetter* 2000; **1**(Aug; 7): www.geneletter.com
127. Billings P. Warp speed genetics. *GeneLetter* 2000; **1**(Sep; 8): www.geneletter.com

128. Billings P. Questioning the question: the role of opposites. *GeneLetter* 2000; **1**(Sep; 8): www.geneletter.com
129. Billings P. On crooks, adverse selection and insurance genetics. *GeneLetter* 2000; **1**(Oct; 9): www.geneletter.com
130. Billings P. Art and genetics: asking the right questions. *GeneLetter* 2000; **1**(Oct; 9): www.geneletter.com
131. Billings P. Practicing responsible genetic medicine. *GeneLetter* 2000; **1**(Nov; 10): www.geneletter.com
132. Billings P. Genetic hygiene: public health anew? *GeneLetter* 2000; **1**(Dec; 11): www.geneletter.com
133. Billings P. Applying genetic advances: where do we go from here. A report from GeneSage's "Genetic issues survey of managed care executives". *GeneLetter* 2000; **1**(Dec; 11): www.geneletter.com
134. Billings P. Paying for the genetic revolution. *GeneLetter* 2001; **1**(Jan; 12): www.geneletter.com
135. Billings P. Hemochromatosis imbroglio. *GeneLetter* 2001; **1**(Jan; 12): www.geneletter.com
136. Billings P. Happy Birthday, GeneLetter. *GeneLetter* 2001; **2**(Feb; 1): www.geneletter.com
137. Billings P. The disappearing gene. *GeneLetter* 2001; **2**(Mar; 2): www.geneletter.com
138. Billings P. Where things stand. *GeneLetter* 2001; **2**(Apr; 3): www.geneletter.com
139. Billings P. Human genetic complexity. *GeneLetter* 2001; **2**(May; 4): www.geneletter.com
140. Billings P. Genetic screening anew. *GeneLetter* 2001; **2**(Aug; 5): www.geneletter.com
141. Billings P. Translating genomics for health care providers and consumers. In: Commercialization of Genomics: Challenges and Opportunities (Ken Rubenstein, editor) Cambridge Healthtech Institute Publishing, Newton Upper Falls, MA 2001: 24-32
142. Spinard P. with Billings P. ReadMe. *Wired* 2001; 9(12): 98
143. Billings P and Koliopoulos S. What is the human genome? In: The ethical eye: the human genome (Jean-Francois Mattei, coordinator) Council of Europe Publishing, Strasbourg, Germany 2001; 19-28

144. Billings P, Rothstein M, Faigman D and Jones R. Cutting edges issues in law and science. Proceedings of a 9th circuit judicial conference panel presentation. In: Scientific Evidence Review Monograph 3 (Cwik C and North J, eds) 2001 ABA Publishing, Chicago, IL. pp1-52
145. Beeson D, Billings P, Darnofsky M, and C Weiner. Ethics, genetic technologies and social responsibility in the 21st century. 2001 Proceedings of a Townsend Center panel. www.lib.berkeley.edu/banc/biotech
146. Koliopoulos S. and Billings P. Genomic testing in insurance and financial benefit markets: a market evaluation. 2002. Private commissioned paper for Sequenom, Inc.
147. Zavos P and Billings P. Should reproductive cloning be made available to people who want their own biologic children? *Ob.Gyn. News* 2002; **37** (5): 4
148. Billings P. Human genomics. *GeneWatch* 2002; **15**(1):3-4
149. Shibata A, Harris D and Billings P. Concentrations of estrogens and IGFs in umbilical cord blood plasma: a comparison among caucasian, hispanic and asian-american females. *J Clin Endo Meta* 2002; **87**(2):810-5
150. Worthy K., Strohmman R., Billings P. Conflicts around a study of Mexican crops. *Nature* 2002; **417**:897.
151. Billings P. A medical geneticist's view. *World Watch* 2002; **15**(4):16
152. Shorett, P., Rabinow P., Billings P. Framing the New Life Sciences. *Nature Biotechnology* 2003; **21**(2):123-5.
153. Billings, P. Your DNA computer: When machines and humans blend. *IHealthBeat* 2002: Sept. 6. www.ihealthbeat.org
154. Worthy K., Strohmman RC, Billings PR and the Berkeley Biotechnology Working Group. Agricultural biotechnology science compromised: the case of Quist and Chapela. In the Year Book of Science and Technology in Society 2004.
155. Billings P. Iron revisited. *Annals of Family Medicine* 2004 Invited online commentary posted 4/1/04 at <http://www.AnnFamMed.org>
156. Billings P and Shorett P Human health implications of genetically modified foods 2004.
157. P.R. Billings and M.P. Brown. The future of clinical laboratory genomics. *M.L.O.* Dec (2004). 8-15. (Published online Dec 1, 2004 at www.mlo-online.com).
158. Williams E, Steenberg K, Brown T, Billings P. Inherited Venous Thrombosis. *Advance*. 2004; May: 68-73.

159. P.R. Billings and M.P. Brown. The future of clinical laboratory genomics. M.L.O. Dec (2004). 8-15. (Published online Dec 1, 2004 at www.mlo-online.com).
160. Billings, P. CRG History A Chapter in Non Governmental Politics, "Standards for Privacy of Individually Identifiable Health Information", National Committee on Vital and Health Statistics, Subcommittee on Privacy and Confidentiality, January 12, 2005, available online at www.ncvhs.hhs.gov/050112p2.htm.
161. Billings P. Genetic nondiscrimination. *Nature Genetics*. 2005;37(6):559-60.
162. Billings P. Genetic privacy and confidentiality: The impact of greater knowledge on rights and power. Testimony before the National Commission on Vital and Health Statistics Subcommittee on Privacy and Confidentiality. *US Government Printing Office*. 2005.
163. Billings P, Carlson R, Carlson J, Cain M, Wilson C, Shorett P, Everett W. Ready for genomic medicine? Perspectives of health care decision makers. *Archives of Internal Medicine*. 2005;165(16):1917-9.
164. Berger B, Schroy P, Rosenberg J, Lai-Goldman M, Eisenberg M, Brown T, Rochelle B, Billings P. Colorectal cancer screening using stool DNA analysis in clinical practice: early clinical experience with respect to patient acceptance and colonoscopic follow-up of abnormal tests. *Clin Colorectal Cancer*. 2006;5(5):338-43.
165. Billings P. Three barriers to innovative diagnostics. *Nature Biotechnology*. 2006;24(8):917-8.
166. Ramsey S, Veenstra D, Garrison L, Carlson R, Billings P, Carlson J, Sullivan S. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. *The American Journal of Managed Care*. 2006;12(4):197-202.
167. Billings P. Stem cell research: Dangerous territory? *New Scientist*. 2006;2576:
168. M.P. Brown, M Lai-Goldman and P.R. Billings, Translational diagnostics: challenges and opportunities. Chapter 31 in: *Handbook of Genomic Medicine*, H.F. Willard and G.S. Ginsburg, eds, (In Press)

BOOKS PUBLISHED:

1. Billings P (ed). DNA on Trial: Genetic Identification and Criminal Justice. Cold Spr Harbor Pubs 1992.

BOOKS AND PUBLICATIONS IN PREPARATION:

1. Billings P. The Rumor of Illness: Disease in the Genetic Age (In preparation).
2. Billings P. Bias in Gene Seeking. (In preparation).

3. Billings P, Matocq L and Johnston P. Legislating the Genome. (In preparation)
4. Billings, P. Identity in the Post Genomic World. (In preparation)
5. Brent R, Rabinow P and Billings P. Genomics and Citizenship (In preparation)

ABSTRACTS:

1. Billings P, Burakoff S, Germain R, Dorf M, and Benacerraf B. H-2I region control of CTL specificity. In: Handbook of Molecular Biology, 1977; UCLA-ICN Conferences.
2. Billings P, Burakoff S, Dorf M, and Benacerraf B. The genetic control of cell-mediated immune responses. National Student Research Forum (report), 1979.
3. Billings P. I-Region specific cytolysis. Eastern Student Research Forum (report), 1979.
4. Billings P, Burke W, Hornung S, Furlong C, and Motulsky A. Genetic studies of red cell sodium-lithium countertransport. *Am J Hum Genet* 1983; **35**:38A.
5. Billings, P, Hornung S, and Motulsky A. Studies on red cell membrane transport of lithium. *Clin Res* 1984; **32**:77A.
6. Billings P. Clinical variability in familial dysautonomia. *Clin Res* 1984; **32**:98A.
7. Billings P, Hornung S, and Motulsky A. Amiloride inhibitable cation transport. *Am J Hum Genet* 1984; **36**:7S.
8. Billings P, Ward R, Hornung S, Burke W, and Motulsky A. A major gene influencing cation transport and susceptibility to essential hypertension. *Clin Res* 1985; **33**:329A.
9. Billings P. Human genetic polymorphisms affecting cation transport. *Genetics* 1985; **110**:515.
10. Billings P, Burd P, Greeman G, Gerald C, Hwang C, Wilson S, Actor J, Berman J, Ko J, and Cantor H. Inducer T cell subsets and activation specific genes. *Amer J Hum Genet* 1986; **39**(3):A25.
11. Billings P. Psychiatric issues in neurofibromatosis. Neurofibromatosis Foundation of America Newsletter 1988.
12. Kuchroo V, Steele J K, Billings P, Selvaraj P, Collins M, and Dorf M. Expression of CD3 associated antigen-binding receptors on suppresser T cells. *Fed Proc* 1989; **3**(4):4985.
13. Billings P, Smith K and Packman S. Discrimination Arising From Genetic Information CPMC/MRI Research Compendium 1992.

14. Billings P. Genetic Discrimination and Neurological Disorder: The Analysis of Sexual Orientation. Fukui International Symposium 1993.
15. Laden V, Barash C, Koenig B, and Billings P. Predicting AIDs and Genetic Illness: The Consequences of and Adaptations to Discrimination. APHA National Meeting 1993.
16. Smith K, Packman S, and Billings P. Discrimination arising from genetic information. *Clin Res* 1994; **42**(1):32(a).
17. Cohen P, Smith M, Weigle E, Cox J, Marshall C and Billings P. All bang, no buck: results of the GeneServices Project. ACMG National Meeting 2001.